PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma
| العنوان: | PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma |
|---|---|
| المؤلفون: | Karolina Bednarska, Colm Keane, Joshua W.D. Tobin, Ashlea Campbell |
| المصدر: | Cells, Vol 10, Iss 1152, p 1152 (2021) Cells |
| بيانات النشر: | MDPI AG, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | 0301 basic medicine, Lymphoma, B-Cell, LAG3, QH301-705.5, Programmed Cell Death 1 Receptor, Follicular lymphoma, Review, Ligands, Nervous System, 03 medical and health sciences, 0302 clinical medicine, follicular lymphoma, Antigens, CD, LAG-3, PD-1, Tumor Microenvironment, medicine, Animals, Humans, Biology (General), B-cell lymphoma, Tumor microenvironment, business.industry, non-Hodgkin lymphoma, Mediastinum, General Medicine, immune checkpoint blockade, Immune Checkpoint Proteins, medicine.disease, Hodgkin Disease, Lymphocyte Activation Gene 3 Protein, diffuse large B cell lymphoma, Immune checkpoint, Lymphoma, Blockade, 030104 developmental biology, Immune System, 030220 oncology & carcinogenesis, Cancer research, Immunotherapy, Lymphoma, Large B-Cell, Diffuse, business, Diffuse large B-cell lymphoma, Hodgkin lymphoma |
| الوصف: | The dependence of cancer on an immunotolerant tumor microenvironment (TME) is well established. Immunotherapies that overcome tumor-induced immune suppression have been central to recent advancements in oncology. This is highlighted by the success of agents that interrupt PD-1 mediated immune suppression in a range of cancers. However, while PD-1 blockade has been paradigm-shifting in many malignancies, the majority of cancers show high rates of primary resistance to this approach. This has led to a rapid expansion in therapeutic targeting of other immune checkpoint molecules to provide combination immune checkpoint blockade (ICB), with one such promising approach is blockade of Lymphocyte Activation Gene 3 (LAG-3). Clinically, lymphoproliferative disorders show a wide spectrum of responses to ICB. Specific subtypes including classical Hodgkin lymphoma have demonstrated striking efficacy with anti-PD-1 therapy. Conversely, early trials of ICB have been relatively disappointing in common subtypes of Non-Hodgkin lymphoma. In this review, we describe the TME of common lymphoma subtypes with an emphasis on the role of prominent immune checkpoint molecules PD-1 and LAG3. We will also discuss current clinical evidence for ICB in lymphoma and highlight key areas for further investigation where synergistic dual checkpoint blockade of LAG-3 and PD-1 could be used to overcome ICB resistance. |
| تدمد: | 2073-4409 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::468252f9ddff0e34aba12a95dcec64ddTest https://doi.org/10.3390/cells10051152Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....468252f9ddff0e34aba12a95dcec64dd |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20734409 |
|---|